Heron Therapeutics: Corporate Presentation (Heron Therapeutics) - Aug 17, 2015 - “SUSTOL, as part of a three-drug regimen, is the first 5-HT3 antagonist to demonstrate superiority to a standard-of-care, three-drug regimen in delayed nausea and vomiting in patients receiving HEC”
P3 data: top line • Oncology
|